News


All series


All News

Amivantamab/lazertinib trumps osimertinib in lung cancer treatment, promising results with nivolumab in dMMR in gynecologic cancers, and Curium’s lutetium-177 submission for SSTR-positive GEP-NETs are featured. Regarding lung cancer, we also cover valuable insights on immunotherapy combinations and breakthrough treatments presented at ASCO.